Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was the recipient of a significant decline in short interest in the month of July. As of July 15th, there was short interest totalling 12,730,000 shares, a decline of 17.9% from the June 30th total of 15,510,000 shares. Based on an average daily volume of 6,250,000 shares, the days-to-cover ratio is presently 2.0 days.

Sangamo Therapeutics Trading Up 28.7 %

Shares of NASDAQ:SGMO traded up $0.19 on Friday, reaching $0.86. 123,708,543 shares of the company’s stock were exchanged, compared to its average volume of 18,010,276. The company has a fifty day moving average of $0.49 and a 200-day moving average of $0.61. Sangamo Therapeutics has a twelve month low of $0.29 and a twelve month high of $1.48. The company has a market capitalization of $179.48 million, a price-to-earnings ratio of -0.46 and a beta of 1.24.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.05). Sangamo Therapeutics had a negative return on equity of 182.55% and a negative net margin of 1,749.06%. The company had revenue of $0.48 million for the quarter, compared to analyst estimates of $8.51 million. During the same period last year, the company posted $0.12 earnings per share. As a group, equities research analysts forecast that Sangamo Therapeutics will post -0.55 EPS for the current fiscal year.

Institutional Trading of Sangamo Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. State Board of Administration of Florida Retirement System raised its position in Sangamo Therapeutics by 61.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 23,650 shares during the last quarter. Mackenzie Financial Corp raised its position in Sangamo Therapeutics by 72.4% in the fourth quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 31,003 shares during the last quarter. Golden State Equity Partners raised its position in Sangamo Therapeutics by 21.0% in the fourth quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 34,960 shares during the last quarter. Assenagon Asset Management S.A. raised its position in Sangamo Therapeutics by 14.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 129,811 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in Sangamo Therapeutics by 4.0% in the first quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock valued at $3,311,000 after purchasing an additional 192,385 shares during the last quarter. 56.93% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on SGMO shares. StockNews.com started coverage on shares of Sangamo Therapeutics in a report on Sunday. They issued a “sell” rating on the stock. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Sangamo Therapeutics in a research report on Wednesday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $5.67.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.